Financial Calendar
16 August - Full Year Result
18 Oct - AGM
Questions about my Shareholding
Please call CSL's share registry ComputerShare on 1800 646 882 for queries regarding address changes, dividend payments, etc.
Life Science Leader
Life Science Leader
Paul Perreault talks about PDF icon The Secrets To CSL Limited's Incredible Revenue Growthin an interview with Life Science Leader.
Investor Contact
Bernard Ronchi
Senior Manager, Investor Relations
Phone: +613 9389 3470
Subscribe to News Alert
To receive the latest updates about CSL, sign up for our email News Alert.

CSL Share Price

Visit our CSL Share Price page to access the quote table and price chart.

About CSL

CSL is a global specialty biotherapeutics company that develops and delivers innovative biotherapies that save lives, and help people with life-threatening medical conditions live full lives.

With major facilities in Australia, Germany, Switzerland, United Kingdom and the U.S., CSL employs over 17,000 employees working in more than 30 countries.

ASX Releases

New Debt Facilities
ASX Announcement

CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that on 4 October 2017 it closed a new USD700 million private placement in the U.S. The private placement was foreshadowed in CSL’s full year announcement in August 2017.


CSL Behring Acquires Biotech Company Calimmune and its Proprietary Stem Cell Gene Therapy Platform
ASX Announcement

CSL Limited today announced that CSL Behring has agreed to acquire Calimmune, Inc., a US biotechnology company focused on the development of ex vivo hematopoietic stem cell (HSC) gene therapy with R&D facilities in Pasadena, California, USA and Sydney, New South Wales, Australia for an upfront payment of $91 million.


Full Year Result 2017
Full Year Results CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of $1,337 million for the 12 months ended 30 June 2017.

CSL Completes Transaction to Acquire a Majority Stake in Chinese Plasma Fractionator
CSL Limited today announced that it has closed a joint venture transaction with Humanwell Healthcare Group Co. Ltd. to acquire a majority stake in plasma-derived therapies manufacturer Wuhan Zhong Yuan Rui De Biological Products Co. Ltd.

CSL Response to Patent Infringement Complaint
ASX Announcement

CSL Limited has become aware that Bioverativ has filed complaints in the U.S. District Court for the District of Delaware and with the International Trade Commission.


HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) FDA Approval
ASX Announcement CSL today announced that the U.S. Food and Drug Administration (FDA) has approved CSL Behring’s HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]), the only subcutaneous therapy indicated for routine prophylaxis to prevent hereditary angioedema (HAE) attacks in adolescent and adult patients.

CSL to acquire majority stake in Chinese plasma fractionator
Wuhan Zhong Yuan Rui De Biologicals Products

ASX Announcement CSL to acquire an 80 per cent stake in plasma-derived therapies manufacturer Wuhan Zhong Yuan Rui De Biologics (“Ruide”) in China for US$352 million.

CSL Response to Patent Complaint
FY2017 profit upgrade CSL remains highly confident that CSL830 does not infringe any valid claim of the Shire ViroPharma patent and will vigorously defend against the claims.

Half Year Result 20171
Half Year Results Announcement 2017 CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of $806 million for the six months ended 31 December 2016, up $87 million or 12% on a reported basis when compared to the prior comparable period (PCP).

Changes to format of CSL Group Financial Statements
ASX Announcement CSL Limited (ASX:CSL; USOTC:CSLLY) today released details of changes in the format of elements of the CSL Group Financial Statements. The disclosures will be applicable from the half year financial statements to be released on 15 February 2017 and will be used in the full year financial statements for the 2016/17 year and subsequent financial statements.

FY2017 profit upgrade
FY2017 profit upgrade CSL Limited (ASX:CSL; USOTC:CSLLY) today upgraded its net profit after tax (NPAT) expectation for FY2017. Following strong sales performance, CSL expects to report NPAT of approximately US$800 million for the six months ended 31 December 2016.

AFSTYLA® (rFVIII), for Haemophilia A, receives European Commission Approval
Afstyla CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that the European Commission has granted marketing authorisation for CSL Behring’s AFSTYLA ® [Recombinant Human Coagulation Factor VIII, Single Chain] for children and adults with haemophilia A.

Prior ASX Releases

>> View the ASX Archive

© 2017 CSL Limited